Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
Dyadic Expands IP Protection and Business Development Activities in Japan
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Dyadic International, Inc. (DYAI) Q4 2025 Earnings Call Transcript
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
Dyadic International (NASDAQ:DYAI) Share Price Crosses Below 50 Day Moving Average – Should You Sell?
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript
Reviewing Dyadic International (NASDAQ:DYAI) and Kezar Life Sciences (NASDAQ:KZR)
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
Bandera Partners LLC Has $1.37 Million Holdings in Dyadic International Inc. $DYAI
Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Dyadic to Present at Investor Conferences and BPI East
Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Dyadic to Present at World Vaccine Congress | Washington
Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript
Dyadic Reports 2024 Year-End Financial Results and Business Updates
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
Dyadic to Attend Multiple Industry Events in March
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Dyadic Expands Global Presence with Participation in Key Industry Events